High-risk superficial bladder cancer: Intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder

H. T. Pham, M. S. Soloway

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The ideal treatment for T1 G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial. Therapeutic options after the initial transurethral (TUR) resection are observation, intravesical therapy, a repeat resection, radiation therapy, and cystectomy. Because more than half of patients with T1 G3 TCC of the urinary bladder do not progress, initial cystectomy can represent overtreatment. However, observation alone following TUR for T1 G3 TCC of the urinary bladder is associated with a progression rate of 48%. Intravesical immunotherapy has been shown to decrease recurrence and progression in high-grade Ta carcinoma in situ and T1 bladder cancer. When patients with T1 G3 tumors are well selected, intravesical therapy following the initial TUR can significantly improve survival and quality of life. Persistence or recurrence of high-grade tumor mandates consideration of cystectomy.

Original languageEnglish
Pages (from-to)147-153
Number of pages7
JournalSeminars in Urologic Oncology
Volume15
Issue number3
StatePublished - Sep 8 1997
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Urinary Bladder Neoplasms
Cystectomy
Urinary Bladder
Observation
Recurrence
Carcinoma in Situ
Therapeutics
Immunotherapy
Neoplasms
Radiotherapy
Quality of Life
Survival

Keywords

  • Bladder
  • Intravesical therapy
  • Superficial bladder cancer
  • Transitional cell carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

High-risk superficial bladder cancer : Intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder. / Pham, H. T.; Soloway, M. S.

In: Seminars in Urologic Oncology, Vol. 15, No. 3, 08.09.1997, p. 147-153.

Research output: Contribution to journalArticle

@article{21d45f301f704975858eebe3821a1711,
title = "High-risk superficial bladder cancer: Intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder",
abstract = "The ideal treatment for T1 G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial. Therapeutic options after the initial transurethral (TUR) resection are observation, intravesical therapy, a repeat resection, radiation therapy, and cystectomy. Because more than half of patients with T1 G3 TCC of the urinary bladder do not progress, initial cystectomy can represent overtreatment. However, observation alone following TUR for T1 G3 TCC of the urinary bladder is associated with a progression rate of 48{\%}. Intravesical immunotherapy has been shown to decrease recurrence and progression in high-grade Ta carcinoma in situ and T1 bladder cancer. When patients with T1 G3 tumors are well selected, intravesical therapy following the initial TUR can significantly improve survival and quality of life. Persistence or recurrence of high-grade tumor mandates consideration of cystectomy.",
keywords = "Bladder, Intravesical therapy, Superficial bladder cancer, Transitional cell carcinoma",
author = "Pham, {H. T.} and Soloway, {M. S.}",
year = "1997",
month = "9",
day = "8",
language = "English",
volume = "15",
pages = "147--153",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - High-risk superficial bladder cancer

T2 - Intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder

AU - Pham, H. T.

AU - Soloway, M. S.

PY - 1997/9/8

Y1 - 1997/9/8

N2 - The ideal treatment for T1 G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial. Therapeutic options after the initial transurethral (TUR) resection are observation, intravesical therapy, a repeat resection, radiation therapy, and cystectomy. Because more than half of patients with T1 G3 TCC of the urinary bladder do not progress, initial cystectomy can represent overtreatment. However, observation alone following TUR for T1 G3 TCC of the urinary bladder is associated with a progression rate of 48%. Intravesical immunotherapy has been shown to decrease recurrence and progression in high-grade Ta carcinoma in situ and T1 bladder cancer. When patients with T1 G3 tumors are well selected, intravesical therapy following the initial TUR can significantly improve survival and quality of life. Persistence or recurrence of high-grade tumor mandates consideration of cystectomy.

AB - The ideal treatment for T1 G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial. Therapeutic options after the initial transurethral (TUR) resection are observation, intravesical therapy, a repeat resection, radiation therapy, and cystectomy. Because more than half of patients with T1 G3 TCC of the urinary bladder do not progress, initial cystectomy can represent overtreatment. However, observation alone following TUR for T1 G3 TCC of the urinary bladder is associated with a progression rate of 48%. Intravesical immunotherapy has been shown to decrease recurrence and progression in high-grade Ta carcinoma in situ and T1 bladder cancer. When patients with T1 G3 tumors are well selected, intravesical therapy following the initial TUR can significantly improve survival and quality of life. Persistence or recurrence of high-grade tumor mandates consideration of cystectomy.

KW - Bladder

KW - Intravesical therapy

KW - Superficial bladder cancer

KW - Transitional cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0030804016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030804016&partnerID=8YFLogxK

M3 - Article

C2 - 9394909

AN - SCOPUS:0030804016

VL - 15

SP - 147

EP - 153

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 3

ER -